Business Wire

YOKOGAWA-ELECTRIC

7.4.2020 09:02:09 CEST | Business Wire | Press release

Share
Yokogawa Releases AI-enabled Versions of SMARTDAC+ Paperless Recorders and Data Logging Software, and Environmentally Robust AI-enabled e-RT3 Plus Edge Computing Platform for Industry Applications

Yokogawa Electric Corporation (TOKYO: 6841) announces the release of artificial intelligence (AI)-enabled versions of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, and GA10 data logging software, which are components of the highly operable and expandable SMARTDAC+TM data acquisition and control system. This new AI functionality includes the future pen, a function developed by Yokogawa that enables the drawing of predicted waveforms. Yokogawa is also releasing a new CPU module for the e-RT3TM Plus edge computing platform that is environmentally robust and PythonTM*1  compatible. The GX/GP and e-RT3 Plus release is set for April 8, and the GA10 software will be released on May 13. The SMARTDAC+ system is a product in the OpreXTM Data Acquisition family, and the e-RT3 Plus is part of the OpreX Control Devices family.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005269/en/

The introduction of AI functions such as the future pen, a first for industrial recorders*2 , will help users identify and correct problems before they have a chance to cause disruptions in production operations.

Background

There is a rising interest in the manufacturing sector in the use of AI to prevent equipment malfunctions and maximize productivity. At the same time, AI technologies have a steep learning curve, and the introduction of existing AI-enabled products and the analysis of their data is typically beyond the expertise of novices to this field.

Recorders are used in manufacturing and R&D to acquire, display, and record data on voltage, current, temperature, flow rate, pressure, and other process variables. Yokogawa is a leading manufacturer of recorders, and also holds a solid track record in the consulting industry with the use of machine learning to predict and analyze both equipment anomalies and product quality for manufacturers. To improve productivity and product quality, Yokogawa is now building user-friendly AI-related functions into its recorders, data logging software, and controllers. For example, these functions now enable GX/GP series recorders to draw waveforms on screen that are predicted based on the real-time analysis of collected data so that users can anticipate and correct problems early on, before they have a chance to escalate. Also, the e-RT3 Plus edge computing platform has been enhanced with the addition of support for Python, a programming language that is widely used in AI R&D.

Enhancements

  1. AI future pen function for drawing of predicted waveforms
    A future pen function has been added to the GX/GP series recorders to enable the drawing of predicted waveforms based on the use of AI to analyze collected data in real time. By viewing predicted waveforms up to a specified time point, users can identify the likelihood that an alarm will occur and take action in advance. An industry first, this adds an entirely new dimension to the capabilities of recorders, whose collection and recording of data has conventionally been used to visualize the past and present performance of various types of equipment.

  2. Detection of anomalies and prediction of potential failures
    A machine learning function has been added to the GA10 data logging software that can acquire normal process values from correctly operating devices and use these values to detect an anomaly and predict a potential failure, a capability that up till now has only been possessed by the most expert operators. Data on which device is expected to fail is displayed on screen, highlighted within a yellow frame. Maintenance can thus be performed before the device fails, minimizing the likelihood of any disruptions to production. This function does not necessitate the collection of abnormal process values and thus is easy to implement.

  3. Addition of Python support
    e-RT3 Plus controllers can be built into various types of devices. For use with these controllers, Yokogawa is releasing a new CPU module that supports Python, a programming language that is widely used in machine learning and other branches of the AI field. The large library of software written in this language includes numerous tools that programmers can use to speed up their development of AI predictive diagnostic functions. This new CPU module also has excellent environmental resistance, and easily accommodates existing input/output (IO) modules. The addition of this new module to the e-RT3 Plus edge computing platform will enable the introduction of AI solutions in a wider range of industries.

For added flexibility, the new e-RT3 Plus controllers run on Linux Ubuntu*3 , a general-purpose operating system.

Major Target Markets
GX series: Production sites in a wide range of industries including iron and steel, electric power, chemicals, pulp and paper, foods, pharmaceuticals, heat treatment equipment, water supply and wastewater treatment, electrical equipment, and electronics
GP series: Companies engaged in R&D of home appliances, automobiles, semiconductors, and new-energy related technologies as well as academic institutions and research institutes
GA10: Both of the above
e-RT3 Plus: Manufacturers of industrial machinery and companies engaged in the assembly of electronic components and devices

Applications
Monitoring and recording of voltage, current, temperature, flow rate, pressure, and other process variables; evaluation of performance in equipment management, production, and product development; safety and reliability evaluation during product quality inspection processes

*1 A versatile programming language that is widely used in AI application development. Designed to be user-friendly with simple code, Python enables users to write various programs in a clear manner with fewer lines of code than other languages. In addition, numerous Python open-source libraries are available for use in machine learning and other AI applications.
*2 Based on a March 2020 Yokogawa survey
*3 A Linux distribution and installation package provided by Canonical Ltd., a UK-based software company

About SMARTDAC+
SMARTDAC+ stands for smart data acquisition and control, and the SMARTDAC+ system includes a variety of IO modules and options. With the product lineup of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, GA10 data logging software, and GM series data acquisition systems, SMARTDAC+ offers extensive support for manufacturing process monitoring and performance evaluation.

For more information
https://www.yokogawa.com/ai-products/

About OpreX
OpreX is the comprehensive brand for Yokogawa's industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa's IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. The SMARTDAC+ data acquisition and control system is part of the OpreX Data Acquisition lineup, which is aligned under the OpreX Measurement category. The OpreX Measurement category includes field equipment and systems for highly precise measurement, data collection, and analysis.

With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.

About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com .

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye